Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Operating Expenses (2017 - 2026)

Lexaria Bioscience's Operating Expenses history spans 10 years, with the latest figure at $1.5 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 49.68% to $1.5 million in Q1 2026 year-over-year; TTM through Feb 2026 was $9.8 million, a 0.79% decrease, with the full-year FY2025 number at $12.6 million, up 102.56% from a year prior.
  • Operating Expenses hit $1.5 million in Q1 2026 for Lexaria Bioscience, down from $1.6 million in the prior quarter.
  • Over the last five years, Operating Expenses for LEXX hit a ceiling of $3.9 million in Q2 2025 and a floor of $813005.0 in Q1 2024.
  • Historically, Operating Expenses has averaged $2.0 million across 5 years, with a median of $1.8 million in 2022.
  • Biggest five-year swings in Operating Expenses: soared 259.78% in 2025 and later tumbled 49.68% in 2026.
  • Tracing LEXX's Operating Expenses over 5 years: stood at $1.8 million in 2022, then dropped by 27.67% to $1.3 million in 2023, then soared by 123.39% to $2.9 million in 2024, then crashed by 45.21% to $1.6 million in 2025, then dropped by 6.46% to $1.5 million in 2026.
  • Business Quant data shows Operating Expenses for LEXX at $1.5 million in Q1 2026, $1.6 million in Q4 2025, and $2.9 million in Q3 2025.